Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-MUC1 CAR T cell/PD-1 knockout engineered T cell therapy - Guangzhou Anjie Biomedical Technology

Next Previous
Drug Profile

Anti-MUC1 CAR T cell/PD-1 knockout engineered T cell therapy - Guangzhou Anjie Biomedical Technology

Alternative Names: Anti-MUC1 CAR T cells and PD-1 knockout engineered T cells; Anti-MUC1 CAR-T cells combined with PD-1 knockout engineered T cells

Latest Information Update: 07 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Guangzhou Anjie Biomedical Technology
  • Developer Guangzhou Anjie Biomedical Technology; Sun Yat-Sen University; The First Affiliated Hospital of Guangdong Pharmaceutical University; University of Technology Sydney
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Gene silencing; Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Breast cancer; Non-small cell lung cancer; Oesophageal cancer

Most Recent Events

  • 02 Jun 2023 Efficacy and adverse events data from a phase I/II trial in Oesophageal cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 16 Nov 2022 Sun Yat-Sen University and Guangzhou Anjie Biomedical Technology complete a phase I/II trial in Breast cancer (Late-stage disease, Recurrent, Second-line therapy or greater, Metastatic disease) in China (Parenteral) (NCT05812326)
  • 24 Mar 2021 Phase-I/II development is ongoing in Non-small cell lung cancer and Oesophageal cancer in China (Parenteral)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top